Murali Ravoori, Abstract Co-Author: Nothing to Disclose

Sheela Singh, Abstract Co-Author: Nothing to Disclose

Rohan Bhavane PhD, Abstract Co-Author: Nothing to Disclose

Bahman Anvari PhD, Abstract Co-Author: Nothing to Disclose

Ananth Annapragada PhD, Abstract Co-Author: Stockholder, Marval Pharma Ltd Stockholder, Alzeca Biosciences LLC Stockholder, Sensulin LLC Stockholder, Abbott Laboratories Stockholder, Johnson & Johnson

Vikas Kundra MD, PhD, Presenter: License agreement, Introgen Therapeutics Inc

James Bankson PhD, Abstract Co-Author: Nothing to Disclose

To assess whether a dual-mode, dual-Gadolinium (DM-Dual Gd) liposomal contrast agent can be used to visualize intraperitoneal ovarian tumors by multimodal magnetic resonance (MR) and near infra-red (NIR) imaging.

DM-Dual Gd was manufactured based on the Dual Gd format for MR, with gadolinium molecules on the surface and within the lumen of the liposome to increase relaxivity, and the NIR agent indocyanine green (ICG) within the lumen. Phosphorus (P) and Gd content were measured by ICP-AES. Female nude mice bearing intraperitoneal Hey A8 human ovarian cancer tumors were injected IV with or without DM-Dual Gd (n=6). Two days later, the animals were imaged by T1-weighted MR. Afterwards, NIR imaging of open abdomen and excised tumors/organs was performed. Signal to noise ratio (SNR) was used to compare tumor enhancement by MR and radiant efficiency to compare tumor signal by NIR imaging. For robustness, experiments were repeated using a second human ovarian cancer (OVCAR-3) model.

Gd content was 60.34 mM and P content was 29.44 mM resulting in a Gd/P ratio of 2.05 per particle. On T1-weighted MR images, intraperitoneal ovarian tumors (HeyA8 or OVCAR3) enhanced compared to control tumors two days after DM-dual Gd injection (SNR, p<.05). As seen in the laporatomy and excised tumors views, HeyA8 or OVCAR3 tumors from animals injected with DM-dual Gd had increased fluorescence compared to control tumors (p<.05).

DM-Dual Gd can be used to visualize intraperitoneal ovarian tumors by MR and NIR imaging in pre-clinical intraperitoneal ovarian cancer mouse models.  

Nearly 75% of patients with ovarian cancer present with intraperitoneal disease; and, the degree of cytoreduction at surgery is one of the most important factors for prognosis. Current imaging is limited in detecting peritoneal disease and surgery relies on the naked eye to identify nodules for resection. The current findings suggest clinical potential for using a single injection of a single nanoparticle (DM-Dual Gd) to localize tumor by MR for pre-surgical planning and by NIR at the time of surgery for resection.

Ravoori, M, Singh, S, Bhavane, R, Anvari, B, Annapragada, A, Kundra, V, Bankson, J, Multimodal Magnetic Resonance and Near Infrared-Fluorescent Imaging of Intraperitoneal Ovarian Cancer Using a Dual-Mode, Dual-Gadolinium Liposomal Contrast Agent.  Radiological Society of North America 2014 Scientific Assembly and Annual Meeting, - ,Chicago IL. http://archive.rsna.org/2014/14013993.html